Corporate Cost Reductions Drive Enzo's Recovery Enzo Biochem reduced costs in SG&A and R&D by 22% and 27%, respectively, during the first half of FY2025, aiding its financial recovery. Operating losses for continuing operations improved by $2.4 million. The company is also exploring strategic alternatives, including potential acquisitions or asset sales, to maximize shareholder value.2